Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Inhibrx Biosciences Inc.

    NASDAQ: INBX · Real-Time Price · USD
    14.63
    0.01 (0.07%)
    At close: Jun 17, 2025, 10:13 AM

    Inhibrx Biosciences Statistics

    Share Statistics

    Inhibrx Biosciences has 14.48M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 14.48M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 72.19%

    Shares Floating

    n/a
    		 9.87M

    Failed to Deliver (FTD) Shares

    n/a
    		 559

    FTD / Avg. Volume

    n/a
    		 0.53%

    Short Selling Information

    The latest short interest is 706.98K, so 4.88% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 706.98K

    Short % of Shares Out

    n/a
    		 4.88%

    Short % of Float

    n/a
    		 6.73%

    Short Ratio (days to cover)

    n/a
    		 7.19

    Valuation Ratios

    The PE ratio is 0.13 and the forward PE ratio is -1.58. Inhibrx Biosciences's PEG ratio is 0.

    PE Ratio

    n/a
    		 0.13

    Forward PE

    n/a
    		 -1.58

    PS Ratio

    n/a
    		 1114.64

    Forward PS

    n/a
    		 1

    PB Ratio

    n/a
    		 1.67

    P/FCF Ratio

    n/a
    		 -1.13

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Inhibrx Biosciences has an Enterprise Value (EV) of 78.38M.

    EV / Sales

    n/a
    		 391.9

    EV / EBITDA

    n/a
    		 0.05

    EV / EBIT

    n/a
    		 -0.4

    EV / FCF

    n/a
    		 -0.4

    Financial Position

    The company has a current ratio of 3.94, with a Debt / Equity ratio of 0.06.

    Current Ratio

    n/a
    		 3.94

    Quick Ratio

    n/a
    		 3.94

    Debt / Equity

    n/a
    		 0.06

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 -0.04

    Interest Coverage

    n/a
    		 -24.57

    Financial Efficiency

    Return on Equity is 1263.3% and Return on Invested Capital is -234.02%.

    Return on Equity

    n/a
    		 1263.3%

    Return on Assets

    n/a
    		 933.56%

    Return on Invested Capital

    n/a
    		 -234.02%

    Revenue Per Employee

    n/a
    		 $1,282.05

    Profits Per Employee

    n/a
    		 $10,817,769.23

    Employee Count

    n/a
    		 156

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 2K

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 3.03% in the last 52 weeks. The beta is -0.28, so Inhibrx Biosciences's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.28

    52-Week Price Change

    n/a
    		 3.03%

    50-Day Moving Average

    n/a
    		 12.55

    200-Day Moving Average

    n/a
    		 14.1

    Relative Strength Index (RSI)

    n/a
    		 60.24

    Average Volume (20 Days)

    n/a
    		 105,538

    Income Statement

    In the last 12 months, Inhibrx Biosciences had revenue of 200K and earned 1.69B in profits. Earnings per share was 114.01.

    Revenue

    n/a
    		 200K

    Gross Profit

    n/a
    		 -2.08M

    Operating Income

    n/a
    		 -331.45M

    Net Income

    n/a
    		 1.69B

    EBITDA

    n/a
    		 1.7B

    EBIT

    n/a
    		 1.7B

    Earnings Per Share (EPS)

    n/a
    		 114.01
    Full Income Statement

    Balance Sheet

    The company has 152.6M in cash and 8.05M in debt, giving a net cash position of 144.55M.

    Cash & Cash Equivalents

    n/a
    		 152.6M

    Total Debt

    n/a
    		 8.05M

    Net Cash

    n/a
    		 144.55M

    Retained Earnings

    n/a
    		 -106.13M

    Total Assets

    n/a
    		 242.64M

    Working Capital

    n/a
    		 179.75M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -194.41M and capital expenditures -2.6M, giving a free cash flow of -197.01M.

    Operating Cash Flow

    n/a
    		 -194.41M

    Capital Expenditures

    n/a
    		 -2.6M

    Free Cash Flow

    n/a
    		 -197.01M

    FCF Per Share

    n/a
    		 -13.61
    Full Cash Flow Statement

    Margins

    Gross margin is -1042.5%, with operating and profit margins of -165724% and 843786%.

    Gross Margin

    n/a
    		 -1042.5%

    Operating Margin

    n/a
    		 -165724%

    Pretax Margin

    n/a
    		 843787%

    Profit Margin

    n/a
    		 843786%

    EBITDA Margin

    n/a
    		 851675%

    EBIT Margin

    n/a
    		 -165724%

    FCF Margin

    n/a
    		 -98503%

    Dividends & Yields

    INBX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 757%

    FCF Yield

    n/a
    		 -88.37%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for INBX.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 155.58

    Graham Upside

    n/a
    		 964.16%

    Scores

    Altman Z-Score

    n/a
    		 24.33

    Piotroski F-Score

    n/a
    		 6

    Add to Watchlist